Current situation and the future of neuroprotective drugs for stroke

Chinese Journal of New Drugs

Volumn 20, Issue 11, 2011, Pages 985-987

  Wang, Yi Long ^a   Zhao, Xing Quan ^a   Wang, Yong Jun ^a   Chen, Pan ^a   Zhang, Qian ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Current situation; Neuroprotective drug; Strategy; Stroke

Indexed keywords

NEUROPROTECTIVE AGENT;

DRUG EFFICACY; NEUROPROTECTION; REVIEW; STROKE;

EID: 84863370310     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. HACKE W, KASTE M, BLUHMKI E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med, 2008, 359(13): 1317-1329.
2. PHILIP M, BENATAR M, FISHER M, et al. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials[J]. Stroke, 2009, 40(2): 577-581.
3. LEES K, ZIVIN J, ASHWOOD T, et al. NXY-059 for acute ischemic stroke[J]. N Engl J Med, 2006, 354(6): 588-600.
4. TEAL P, DAVIS S, HACKE W, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)[J]. Stroke, 2009, 40(11): 3518-3525.
5. EHRENREICH H, WEISSENBORN K, PRANGE H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke[J]. Stroke, 2009, 40(12): e647-e656.
6. Stroke therapy academic industry roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development[J]. Stroke, 1999, 30(12): 2752-2758.
7. FISHER M, FEUERSTEIN G, DAVID W, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations[J]. Stroke, 2009, 40(6): 2244-2250.